Sjögren’S Disease
‘Vulnerable to severe infection’: Sjögren’s mortality risk 70% higher vs general population
Mortality risk among patients with Sjögren’s disease is elevated as much as 70% vs. the general population, primarily due to infections and driven by heart and lung involvement, according to data published in The Journal of Rheumatology.
Non-invasive, saliva-based Sjögren’s diagnosis model shows good performance
A non-invasive diagnostic model, based partially on saliva samples, distinguished between patients with and without Sjögren’s disease with high sensitivity and specificity, according to data published in Arthritis Research & Therapy.
Name changes for Sjögren’s, axial spondyloarthritis ‘a big deal’ for researchers, patients
“Ankylosing spondylitis”? “Sjögren’s syndrome”?
FDA grants breakthrough therapy designation to nipocalimab for Sjögren’s disease
The FDA has granted breakthrough therapy designation to nipocalimab, a novel neonatal Fc receptor blocker, for the treatment of moderate to severe Sjögren’s disease, according to a press release from Johnson & Johnson.
Systemic treatment reduces risk for new Sjögren’s disease activity in presence of lymphoma
Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.
Disease activity, symptom burden can indicate Sjögren’s treatment strategy
SAN DIEGO — Determining which of several phenotypes a patient with Sjögren’s disease falls under can help inform their treatment strategy, according to data presented at the 2024 Congress of Clinical Rheumatology West.
World Sjögren’s Day shines light on a disease that too often goes years without diagnosis
Despite being the second-most common rheumatic autoimmune disease in the United States, Sjögren’s syndrome remains under-recognized, with patients often waiting 3 years for a proper diagnosis, according to the Sjögren’s Foundation.
‘Proof of concept’ established for FcRn receptor blocker nipocalimab in Sjogren’s disease
Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate significant improvement vs. those who receive placebo at week 24, according to data presented at the EULAR 2024 Congress.
Sjögren’s spotlight: Everything you’ve missed for Sjögren’s Awareness Month
Sjögren’s disease is one of the most common autoimmune diseases but one of the least known, so to raise awareness of the condition, April is designated Sjögren’s Awareness Month.
Patients with prior sinusitis have greater rheumatic disease risk
Patients with prior sinusitis demonstrate an increased risk for many rheumatic diseases, including antiphospholipid syndrome, Sjögren’s disease and seronegative rheumatoid arthritis, according to data published in RMD Open.